Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | FEN1 | P39748 | 3/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7048301 | 0.91 | PTGS2 (0.50) | KMOLMNANPSR1PTGS2PTGS1 | |
| SCHEMBL7044091 | 0.91 | PTGS2 (0.50) | KMOLMNANPSR1PTGS2PTGS1 | |
| SCHEMBL6723777 | 0.88 | KMO (0.46) | KMONPSR1PTGS2PTGS1FEN1 | |
| SCHEMBL7539544 | 0.88 | PTGS2 (0.50) | KMOPTGS2PTGS1FEN1ALOX5AP | |
| SCHEMBL7048176 | 0.88 | KMO (0.45) | KMOPTGS2PTGS1FEN1ALOX5AP | |
| SCHEMBL7042025 | 0.88 | PTGS2 (0.53) | KMOPTGS2PTGS1SCN9AGLO1 | |
| SCHEMBL7546410 | 0.88 | PTGS2 (0.49) | KMOPTGS2PTGS1FEN1ALOX5AP | |
| SCHEMBL7543924 | 0.87 | PTGS2 (0.47) | KMOPTGS2PTGS1FEN1ALOX5AP | |
| SCHEMBL7548196 | 0.87 | PTGS2 (0.47) | KMOPTGS2PTGS1FEN1ALOX5AP | |
| SCHEMBL7543956 | 0.87 | PTGS2 (0.46) | KMOPTGS2PTGS1FEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | KMO 853/4885LMNA 4037/4885NPSR1 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.